UY33715A - Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a) - Google Patents
Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a)Info
- Publication number
- UY33715A UY33715A UY0001033715A UY33715A UY33715A UY 33715 A UY33715 A UY 33715A UY 0001033715 A UY0001033715 A UY 0001033715A UY 33715 A UY33715 A UY 33715A UY 33715 A UY33715 A UY 33715A
- Authority
- UY
- Uruguay
- Prior art keywords
- human
- tl1a
- league
- disorders
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se da a conocer un anticuerpo completamente humano o fragmento de unión al antígeno de un anticuerpo humano que se une específicamente e inhibe el ligando lA de tipo TNF humano (hTLIA). Los anticuerpos anti-hTL1A humanos son útiles para tratar enfermedades o trastornos asociados al TL1A, tales como enfermedades o trastornos inflamatorios, tales como enteropabas inflamatorias, que incluyen colitis ulcerosa y enfermedad de Crohn, artritis reumatoide y similares; enfermedades o trastornos autoinmunitarios, tales como esclerosis múltiple, diabetes y similares; y reacciones alérgicas, tales como el asma y la inflamación alérgica del pulmón.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41127610P | 2010-11-08 | 2010-11-08 | |
US201161478309P | 2011-04-22 | 2011-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33715A true UY33715A (es) | 2012-05-31 |
Family
ID=45002143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033715A UY33715A (es) | 2010-11-08 | 2011-11-08 | Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a) |
Country Status (21)
Country | Link |
---|---|
US (3) | US8642741B2 (es) |
EP (1) | EP2638069B1 (es) |
JP (2) | JP6076911B2 (es) |
KR (1) | KR101896129B1 (es) |
CN (1) | CN103261228B (es) |
AR (1) | AR083785A1 (es) |
AU (1) | AU2011326097B2 (es) |
BR (1) | BR112013011245A2 (es) |
CA (1) | CA2816799C (es) |
CL (1) | CL2013001279A1 (es) |
EA (1) | EA030397B1 (es) |
IL (1) | IL226172A (es) |
JO (1) | JO3375B1 (es) |
MX (1) | MX355580B (es) |
MY (1) | MY185006A (es) |
NZ (2) | NZ610294A (es) |
SG (2) | SG10201504265RA (es) |
TW (1) | TWI606118B (es) |
UY (1) | UY33715A (es) |
WO (1) | WO2012064682A1 (es) |
ZA (1) | ZA201304114B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
AU2012311288B2 (en) | 2011-09-19 | 2017-08-17 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
JP2014531210A (ja) * | 2011-09-30 | 2014-11-27 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | TL1aに対する抗体およびその使用 |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
BR112015010691A2 (pt) | 2012-11-13 | 2017-08-22 | Regeneron Pharma | Anticorpo que se liga especificamente ao receptor de procineticina (prokr), seu uso no tratamento ou atenuação da dor e composição farmacêutica que o compreende |
MY173334A (en) * | 2013-01-02 | 2020-01-16 | Ichnos Sciences SA | Antibodies that bind to tl1a and their uses |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
BR112015024752A2 (pt) | 2013-03-27 | 2017-07-18 | Cedars Sinai Medical Center | mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
CN105814081B (zh) * | 2013-11-13 | 2021-02-02 | 辉瑞大药厂 | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 |
US10160805B2 (en) | 2014-07-11 | 2018-12-25 | New York University | Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody |
WO2016077720A1 (en) * | 2014-11-14 | 2016-05-19 | Protein One, Llc | Binding agents and uses thereof |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
WO2017077715A1 (en) * | 2015-11-02 | 2017-05-11 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
EA039084B1 (ru) * | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Антитела к tl1a и их применения |
US10322174B2 (en) | 2016-10-26 | 2019-06-18 | Cedars-Sinai Medical Center | Neutralizing anti-TL1A monoclonal antibodies |
MX2019015304A (es) * | 2017-06-21 | 2020-02-17 | Cephalon Inc | Amortiguador de lavado para cromatografia de intercambio cationico. |
CN112585165A (zh) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
RU2689522C1 (ru) * | 2018-09-11 | 2019-05-28 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок, состоящий из растворимого внеклеточного домена человеческого tnfr1 и константной части тяжёлой цепи человеческого igg4 |
CA3121162A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
CA3180632A1 (en) * | 2020-06-03 | 2021-12-09 | Cedars-Sinai Medical Center | Methods and systems for measuring post-operative disease recurrence |
PE20231681A1 (es) * | 2021-02-18 | 2023-10-19 | Prometheus Biosciences Inc | Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos |
EP4294443A1 (en) * | 2021-02-18 | 2023-12-27 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the lung |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
CA2381284A1 (en) * | 1999-08-04 | 2001-02-15 | Amgen Inc. | Fhm, a novel member of the tnf ligand supergene family |
CA2467738A1 (en) * | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US20090317388A1 (en) * | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
ES2611307T3 (es) * | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
CA2694396A1 (en) * | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binding agents directed to kdr and uses thereof - 035 |
JP5745854B2 (ja) * | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Tl1aに対するヒト化抗体 |
JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
-
2011
- 2011-10-31 JO JOP/2011/0327A patent/JO3375B1/ar active
- 2011-11-07 AR ARP110104149A patent/AR083785A1/es unknown
- 2011-11-07 TW TW100140461A patent/TWI606118B/zh not_active IP Right Cessation
- 2011-11-08 AU AU2011326097A patent/AU2011326097B2/en not_active Ceased
- 2011-11-08 UY UY0001033715A patent/UY33715A/es unknown
- 2011-11-08 EP EP11785543.7A patent/EP2638069B1/en active Active
- 2011-11-08 KR KR1020137014739A patent/KR101896129B1/ko active IP Right Grant
- 2011-11-08 MX MX2013005141A patent/MX355580B/es active IP Right Grant
- 2011-11-08 MY MYPI2013700737A patent/MY185006A/en unknown
- 2011-11-08 BR BR112013011245-0A patent/BR112013011245A2/pt not_active Application Discontinuation
- 2011-11-08 SG SG10201504265RA patent/SG10201504265RA/en unknown
- 2011-11-08 EA EA201370105A patent/EA030397B1/ru unknown
- 2011-11-08 CA CA2816799A patent/CA2816799C/en active Active
- 2011-11-08 JP JP2013537924A patent/JP6076911B2/ja active Active
- 2011-11-08 NZ NZ610294A patent/NZ610294A/en not_active IP Right Cessation
- 2011-11-08 SG SG2013034764A patent/SG190176A1/en unknown
- 2011-11-08 WO PCT/US2011/059675 patent/WO2012064682A1/en active Application Filing
- 2011-11-08 US US13/291,145 patent/US8642741B2/en active Active
- 2011-11-08 NZ NZ706986A patent/NZ706986A/en not_active IP Right Cessation
- 2011-11-08 CN CN201180059396.1A patent/CN103261228B/zh active Active
-
2013
- 2013-05-05 IL IL226172A patent/IL226172A/en active IP Right Grant
- 2013-05-08 CL CL2013001279A patent/CL2013001279A1/es unknown
- 2013-06-05 ZA ZA2013/04114A patent/ZA201304114B/en unknown
- 2013-12-31 US US14/144,800 patent/US9556277B2/en active Active
-
2016
- 2016-09-12 JP JP2016177515A patent/JP6272970B2/ja active Active
- 2016-12-15 US US15/380,696 patent/US20170096491A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33715A (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a) | |
PH12020552178A1 (en) | Anti-il36r antibodies | |
PE20130646A1 (es) | Anticuerpos antagonistas anti receptor de il-7 y procedimientos | |
UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
UA115540C2 (uk) | Антитіло до il-36r | |
EA201590412A1 (ru) | Композиции антител и их применения | |
CL2011002744A1 (es) | Anticuerpo anti il-17f monoclonal; composicion farmaceutica; uso de dicho anticuerpo para artritis reumatoide, enfermedad de crohn, psoriasis, esclerosis multiple, enfermedad pulmonar obstructiva cronica o asma en un sujeto. | |
PE20180315A1 (es) | Anticuerpos para cd40 | |
NZ630363A (en) | Anti-kit antibodies and uses thereof | |
PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
BR112016021083A2 (pt) | Conjugados anticorpo-fynomer | |
IN2014DN08025A (es) | ||
PE20141568A1 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina | |
PE20140247A1 (es) | Anticuerpos anti-cd38 | |
CR20150153A (es) | Tratamiento para artitris reumatoide | |
JOP20140049B1 (ar) | أجسام مضادة ترتبط بـ il-23 | |
EA201290360A1 (ru) | Гуманизированные антитела против il-22ra человека | |
CL2012002217A1 (es) | Polipeptido aislado que comprende cuando menos un monómero de un solo dominio variable de un agente nb que se enlaza a dr5 humano; metodo para la prevencion y/o el tratamiento de un trastorno que se puede tratar mediante la mejora de la apoptosis celular. | |
CL2012003538A1 (es) | Anticuerpo especifico anti-s100a4 con actividad antiangiogenica o un fragmento del mismo producido por un hibridoma seleccionado del grupo ecacc 10022401, ecacc 11051801, ecacc 11051802, ecacc 11051803 y ecacc 11051804; lineas celulares que lo producen; composición farmacéutica que la comprende; uso del anticuerpo para tratar enfermedad asociada con inflamación. | |
NZ711704A (en) | Pan-elr+ cxc chemokine antibodies | |
ECSP12012202A (es) | Anticuerpos il-25 humanizados | |
ECSP14029713A (es) | Moléculas de unión il-6 | |
ECSP14030942A (es) | Anticuerpos de anti-transglutaminasa 2 | |
UY33651A (es) | Anticuerpos anti-il12rbeta1 y su uso para tratar los trastornos autoinmunes e inflamatorios | |
AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer |